Key Players in Cancer B/D-HPP
Key Players
Body Fluids Other Than Plasma: Daniel Chan, Ruedi Aebersold, David Speicher
Breast Cancer: Bill Hancock, Gil Omenn, Steve Carr, Peter James
Cancer Biomarkers from Different Cancers: Sudhir Srivastava, Jacob Kagan
Colon Cancer: Ed Nice, Connie Jimenez, Mark Baker
Connections Ca-B/D-HPP to C-HPP: Young-Ki Paik, Bill Hancock
Lung Cancer: Sam Hanash
Ovarian Cancer: Karin Rodland, Zhen Zhang
Pathway Analysis and Cancer Biology: Pier P. Pandolfi
Plasma Atlas, Peptide Atlas, MRM Atlas: Ruedi Aebersold, Robert Moritz
Prostate Cancer: Hui Zhang
Proteogenomics of tumors, assay development, public data release and assay portal:
Henry Rodriguez, Christopher Kinsinger
Tissue Targets: Josip Blender
Key Technologies Involved
-
The high-content application of affinity or antibody-based technologies: antibody microarray, protein microarray, nucleic acid-programmable protein array (NAPPA) - Jashua Labaer, Michael Snyder
-
The mass spectrometry (MS)-based platforms (MS/MS): selected reaction monitoring (SRM) or targeted data extraction for candidate proteins from SWATH MS data - Ruedi Aebersold, Robert Moritz, Mary Lopez, Ranganathan, Amanda Paulovich
-
Hybrid methods: immuno-MS such as SISCAPA-MRM - Amanda Paulovich, Steve Carr
-
Protein modification based assays including phosphoproteins and glycoproteins - Hui Zhang, Ruedi Aebersold, Richard Drake
-
The traditional antibody-based approaches: Western Blots, ELISA, Immunohistochemistry, etc. - Daniel Chan
-
Possibly aptamers - Larry Gold
Locations
Cells, animal models, patient tissues, body fluids
Appropriate NORMAL controls with good inclusion and exclusion data – Akhilesh Pandey, Bernard Kuster